Ulrik N. Jeppesen, Ditte L. Vernal, Anne Sofie Due, Lise S. Mariegaard, Amy E. Pinkham, Stephen F. Austin, Maarten Vos, Mads J. Christensen, Nina K. Hansen, Lisa C. Smith, Carsten Hjorthøj, Wim Veling, Merete Nordentoft, Louise B. Glenthøj
{"title":"Virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trial","authors":"Ulrik N. Jeppesen, Ditte L. Vernal, Anne Sofie Due, Lise S. Mariegaard, Amy E. Pinkham, Stephen F. Austin, Maarten Vos, Mads J. Christensen, Nina K. Hansen, Lisa C. Smith, Carsten Hjorthøj, Wim Veling, Merete Nordentoft, Louise B. Glenthøj","doi":"10.1038/s41591-025-03880-8","DOIUrl":null,"url":null,"abstract":"<p>Paranoia is a distressing and prevalent symptom in schizophrenia spectrum disorders. Virtual reality-based cognitive behavioral therapy for paranoia (VR-CBTp) has been proposed to augment behavioral interventions by providing controlled and safe virtual environments in which social situations inducing paranoid anxiety can be manipulated, allowing for new therapeutical possibilities such as gradual exposure and repetition. This assessor-masked, randomized parallel group superiority trial investigated the efficacy of VR-CBTp compared to standard CBTp. Participants were randomized to receive ten sessions of VR-CBTp or CBTp, both on top of treatment as usual. Intention-to-treat analyses included 254 participants (VR-CBTp: <i>n</i> = 126, CBTp: <i>n</i> = 128). Outcomes were assessed at baseline, treatment cessation and follow-up (6 months after treatment cessation). The primary outcome was Ideas of Persecution subscale from the Green Paranoid Thoughts Scale, measured at treatment cessation. There was not a statistically significant between-group difference on the primary outcome at endpoint (effect estimate: 2% in favor of VR-CBTp; 95% confidence interval: −11% to +17%; Cohen’s <i>d</i> = 0.04; <i>P</i> = 0.77, based on exponentiated log-transformed data). No deaths or violent incidents involving law enforcement occurred during the study. In conclusion, VR-CBTp was not superior to CBTp in reducing schizophrenia-spectrum-disorders-related paranoia. ClinicalTrials.gov registration: NCT04902066.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"95 1","pages":""},"PeriodicalIF":50.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03880-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Paranoia is a distressing and prevalent symptom in schizophrenia spectrum disorders. Virtual reality-based cognitive behavioral therapy for paranoia (VR-CBTp) has been proposed to augment behavioral interventions by providing controlled and safe virtual environments in which social situations inducing paranoid anxiety can be manipulated, allowing for new therapeutical possibilities such as gradual exposure and repetition. This assessor-masked, randomized parallel group superiority trial investigated the efficacy of VR-CBTp compared to standard CBTp. Participants were randomized to receive ten sessions of VR-CBTp or CBTp, both on top of treatment as usual. Intention-to-treat analyses included 254 participants (VR-CBTp: n = 126, CBTp: n = 128). Outcomes were assessed at baseline, treatment cessation and follow-up (6 months after treatment cessation). The primary outcome was Ideas of Persecution subscale from the Green Paranoid Thoughts Scale, measured at treatment cessation. There was not a statistically significant between-group difference on the primary outcome at endpoint (effect estimate: 2% in favor of VR-CBTp; 95% confidence interval: −11% to +17%; Cohen’s d = 0.04; P = 0.77, based on exponentiated log-transformed data). No deaths or violent incidents involving law enforcement occurred during the study. In conclusion, VR-CBTp was not superior to CBTp in reducing schizophrenia-spectrum-disorders-related paranoia. ClinicalTrials.gov registration: NCT04902066.
偏执是精神分裂症谱系障碍中一种令人痛苦的普遍症状。基于虚拟现实的偏执认知行为疗法(VR-CBTp)已经被提出,通过提供可控和安全的虚拟环境来增强行为干预,在虚拟环境中,可以操纵引起偏执焦虑的社会情境,允许新的治疗可能性,如逐渐暴露和重复。这项评估器屏蔽、随机平行组优势试验研究了VR-CBTp与标准CBTp的疗效。参与者随机接受10次VR-CBTp或CBTp治疗,两者都是在常规治疗的基础上进行的。意向治疗分析包括254名参与者(VR-CBTp: n = 126, CBTp: n = 128)。在基线、停止治疗和随访(停止治疗后6个月)时评估结果。主要结果是绿色偏执思想量表中的迫害观念子量表,在治疗停止时测量。在终点的主要结局上,组间差异无统计学意义(效应估计:2%赞成VR-CBTp;95%置信区间:−11%至+17%;Cohen’s d = 0.04;P = 0.77,基于指数对数转换数据)。研究期间没有发生涉及执法的死亡或暴力事件。综上所述,VR-CBTp在减少精神分裂症谱系障碍相关偏执方面并不优于CBTp。ClinicalTrials.gov注册:NCT04902066。
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.